Modelled DT Structure
Method: loop building
Template PDB: 6LR0_U
Identity: 99.924%
Minimized Score: -2429.527 kcal/mol
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0014 | ||||
Gene Name | ABCB11 | ||||
Protein Name | Bile salt export pump | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method: loop building Template PDB: 6LR0_U Identity: 99.924% Minimized Score: -2429.527 kcal/mol Detail: Structure Info |
||||
Synonyms | ABC16; ABCB11; ATP-binding cassette sub-family B member 11; BRIC2; BSEP; PFIC-2; PFIC2; PGY4; SPGP | ||||
DT Family | ATP-Binding Cassette (ABC) Superfamily | ||||
Multidrug Resistance Exporter (MDR) Family (ABCB) | |||||
Tissue Specificity | Expressed predominantly, if not exclusively inthe liver, where it was further localized to the canalicularmicrovilli and to subcanalicular vesicles of the hepatocytes by insitu. | ||||
Function | This transporter involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes. | ||||
Disease(s) | Hypercholesterolemia [ICD-11: 5C80.0] | ||||
Endogenous Substrate(s) | Congugated bile salts; Glycine conjugates; Taurine conjugates; Unconjugated bile salts; Glycochenodeoxycholate; Glycocholate; Taurochenodeoxycholate | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(α) Microbiota Influence of This DT |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
(ε) Exogenous Modulation of This DT |
|||||
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
(α) Mutation-induced Structural Variation |
|||||
(β) Inter-species Structural Differences |
|||||
(γ) Outward/inward-facing Conformation |
|||||
(δ) Xenobiotics-regulated Structural Variability |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(α) Genetic Polymorphisms of This DT |
|||||
(β) Disease-specific Protein Abundances of This DT |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
Molecular Transporting Profile of This DT | |||||
Full List of Drug(s) Transported by This DT |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 4 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Ezetimibe
|
Approved | Drug Info | Hypercholesterolemia | 5C80.0 | [1] |
Glimepiride
|
Approved | Drug Info | Diabetes | 5A10-5A14 | [1] |
Glipizide
|
Approved | Drug Info | Diabetes | 5A10-5A14 | [1] |
Pravastatin
|
Approved | Drug Info | Hypercholesterolemia | 5C80.0 | [2] |
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 2 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Sodium taurocholate
|
Preclinical | Drug Info | Type 2 diabetes | 5A11 | [2] |
Taurocholic acid
|
Terminated | Drug Info | Type 2 diabetes | 5A11 | [3] |
Endogenous Metabolites (EMs) Handled by This DT |
|||||
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 1 EMs in Total | ||||
EM Name | PubChem CID | Detail | Experimental Material | Ref | |
Estradiol-17beta-glucuronide | EM Info | Unclear experiment used for identifying this EM | [4] | ||
Drug-DT Affinity Assessed by Cell Line |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Pravastatin | Approved | Drug Info | Human embryonic kidney cells (HEK293)-BSEP | Km = 124 microM | [2] |
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 3 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Sodium taurocholate | Preclinical | Drug Info | Human embryonic kidney cells (HEK293)-BSEP | Km = 4.64 microM | [2] |
Sodium taurocholate | Preclinical | Drug Info | Spodoptera frugiperda (Sf9) cells-BSEP | Km = 15 microM | [5] |
Taurocholic acid | Terminated | Drug Info | High five cells-BSEP | Km = 4.25 microM | [6] |
References | |||||
1 | Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. | ||||
2 | Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82. | ||||
3 | Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8. | ||||
4 | Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions. Drug Metab Dispos. 2018 May;46(5):567-580. | ||||
5 | Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab Dispos. 2009 Sep;37(9):1878-86. | ||||
6 | The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.